A growing number of studies use data before and after treatment initiation in groups exposed to different treatment strategies to estimate "causal effects" using a ratio measure called the prior event rate ratio (PERR). Here, we offer a causal interpretation for PERR and its additive scale analog, the prior event rate difference (PERD). We show that causal interpretation of these measures requires untestable rate-change assumptions about the relationship between 1) the change of the counterfactual rate before and after treatment initiation in the treated group under hypothetical intervention to implement the control strategy; and 2) the change of the factual rate before and after treatment initiation in the control group. The rate-change assumption is on the multiplicative scale for PERR but on the additive scale for PERD; the 2 assumptions hold simultaneously under testable, but unlikely, conditions. Even if investigators can pick the most appropriate scale, the relevant rate-change assumption might not hold exactly, so we describe sensitivity analysis methods to examine how assumption violations of different magnitudes would affect study results. We illustrate the methods using data from a published study of proton pump inhibitors and pneumonia.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7784529PMC
http://dx.doi.org/10.1093/aje/kwaa122DOI Listing

Publication Analysis

Top Keywords

causal interpretation
12
prior event
12
event rate
12
treatment initiation
12
rate ratio
8
rate difference
8
perr additive
8
additive scale
8
rate treatment
8
rate-change assumption
8

Similar Publications

Malnutrition affects over 30 million children annually and has profound immediate and enduring repercussions. Survivors often suffer lasting neurocognitive consequences that impact academic performance and socioeconomic outcomes. Mechanistic understanding of the emergence of these consequences is poorly understood.

View Article and Find Full Text PDF

Uncovering the epigenetic regulatory clues of PRRT1 in Alzheimer's disease: a strategy integrating multi-omics analysis with explainable machine learning.

Alzheimers Res Ther

January 2025

Zhejiang Provincial Key Laboratory of Pathophysiology, School of Medicine, Ningbo University, 818 Fenghua Road, Jiangbei District, Ningbo, China.

Background: Alzheimer's disease (AD) is a complex neurodegenerative disorder with a largely unexplored epigenetic landscape.

Objective: This study employs an innovative approach that integrates multi-omics analysis and explainable machine learning to explore the epigenetic regulatory mechanisms underlying the epigenetic signature of PRRT1 implicated in AD.

Methods: Through comprehensive DNA methylation and transcriptomic profiling, we identified distinct epigenetic signatures associated with gene PRRT1 expression in AD patient samples compared to healthy controls.

View Article and Find Full Text PDF

Recommended antibiotic treatment agreement between infectious diseases specialists and ChatGPT.

BMC Infect Dis

January 2025

Department of Infectious Diseases, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 15 Vasco de Quiroga, Belisario Domínguez Secc 16 Tlalpan, Mexico City, 14080.

Background: Antimicrobial resistance is a global threat to public health. Chat Generative Pre-trained Transformer (ChatGPT) is a language model tool based on artificial intelligence. ChatGPT could analyze data from antimicrobial susceptibility tests in real time, especially in places where infectious diseases (ID) specialists are not available.

View Article and Find Full Text PDF

In cell line perturbation experiments, a collection of cells is perturbed with external agents and responses such as protein expression measured. Due to cost constraints, only a small fraction of all possible perturbations can be tested in vitro. This has led to the development of computational models that can predict cellular responses to perturbations in silico.

View Article and Find Full Text PDF

Background: Small Bowel Adenocarcinoma (SBA) is a rare gastrointestinal cancer with a limited understanding of the molecular pathology. This study aims to bridge the knowledge gap, providing a robust molecular foundation for SBA and addressing the clinical challenges inherent in treating this orphan disease. The study proposes to redefine the clinical management for SBA patients through advanced molecular profiling techniques to improve potential precision medicine.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!